MDM2 and cancer: The major optimization efforts with this class of inhibitors focused on physicochemical properties, which influence in vivo toxicological outcomes, and yielded NVP-CGM097 with an MDM2 binding affinity of IC50 = 1.7 nM and cell activity of IC50 < 450 nM in wt-p53 cancer cells (Table 1).